3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
49
Carcinoma, Renal Cell
30
Neoplasm Metastasis
18
Neoplasms
15
Kidney Neoplasms
14
Neuroendocrine Tumors
11
Carcinoma, Neuroendocrine
9
Prostatic Neoplasms
7
Melanoma
7
Triple Negative Breast Neoplasms
6
Thyroid Neoplasms
6
Sarcoma
6
Meningioma
6
Lymphoma
6
Glioma
6
Endometrial Neoplasms
6
Tuberous Sclerosis
5
Stomach Neoplasms
5
Recurrence
5
Lymphoma, Mantle-Cell
5
Head and Neck Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Hepatocellular
5
Carcinoma
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Liver Neoplasms
4
Carcinoma, Islet Cell
4
Astrocytoma
4
Interventions
Glutamine
2
sagopilone
1
nicotinamide-beta-riboside
1
allantoicase
1
Vitamin D
1
Vitamin B 6
1
Vitamin B 12
1
Taxoids
1
Tadalafil
1
Sirolimus
1
Prednisolone
1
Paclitaxel
1
Minocycline
1
Metformin
1
Losartan
1
Hydroxychloroquine
1
G(M1) Ganglioside
1
Fatty Acids, Omega-3
1
Exercise
1
Everolimus
1
Etoricoxib
1
Ethosuximide
1
Epoetin Alfa
1
Dietary Supplements
1
Dexamethasone
1
Cryotherapy
1
Bortezomib
1
BID protein, human
1
Acupuncture Therapy
1
Acetylcysteine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Peripheral Nervous System Diseases
×
Everolimus
×
Clear all
NCT01490476
2017-05-23
AFINF2
Assistance Publique - Hôpitaux de Paris
Phase 2
Completed
10 enrolled